Meridia Weight Loss Drug Pulled from U.S. Markets
Abbot Laboratories (Abbot Park, IL) has announced a voluntary withdrawal of its obesity drug Meridia in the United States, according to an FDA announcement made on October 8. The active ingredient in Meridia is sibutramine
Abbot Laboratories (Abbot Park, IL) has announced a voluntary withdrawal of its obesity drug Meridia in the United States, according to an FDA announcement made on October 8. The active ingredient in Meridia is sibutramine.
Approved back in 1997, Meridia has been clinically shown to reduce body weight in obese subjects by 5% compared to diet and exercise alone, but other clinical data suggest the drug is not safe for heart health.
“Meridia’s continued availability is not justified when you compare the very modest weight loss that people achieve on this drug to their risk of heart attack or stroke,” said John Jenkins, MD, director of the Office of New Drugs in FDA’s Center for Drug Evaluation and Research (CDER). “Physicians are advised to stop prescribing Meridia to their patients and patients should stop taking this medication.”
FDA’s request to pull Meridia is based on evidence recorded in the Sibutramine Cardiovascular Outcomes Trial (SCOUT) in which serious heart health events like non-fatal stroke heart attack and stroke were increased by 16% with Meridia use.
Meridia was banned in Europe in January.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
CRN NY State lawsuit update: Dispatch from SupplySide East 2024
April 18th 2024CRN's Steve Mister updates Nutritional Outlook about its ongoing litigation against NY State. The organization sued the state to prevent the enforcement of law that bans sale of weight management supplements to minors.
Microalgae extract supports metabolic health and bone mass during diet and exercise routine
April 11th 2024The extract from Microphyt, called PhaeOptim, was shown to complement weight management strategies that include diet and exercise by support bone mass, aerobic capacity, resting heart rate, and blood lipid profiles.
